ClinicalTrials.gg
RecruitingNCT07003334PDICIUpdated Jun 4, 2025

Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer

An observational study in Gastric Cancers, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
268
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University — 13 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · Nanfang Hospital, Southern Medical University.

Started
2025
with 4 others
Observational
9 of 24
5 open now
Primary completion
2026-12
later than 11 of 13 live
Registered
18th of 24
by date

Among the 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University, this one is one of 5 that started in 2025, is one of 9 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 18th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

13 of the 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Stomach Neoplasms by Nanfang Hospital, Southern Medical University, or all of them as a file.
02

Study summary

  1. Background Gastric cancer (GC) is a leading global cause of cancer-related mortality, with over 1 million new cases and 769,000 deaths in 2020. In China, 80% of patients present with advanced disease, for whom perioperative chemotherapy, surgery, and lymphadenectomy are standard. Recent phase III trials (Checkmate-649, KEYNOTE-062, ORIENT-16) demonstrate that immune checkpoint inhibitors (ICIs) combined with chemotherapy improve progression-free survival (PFS: 2.8-10.5 months) and overall survival (OS: 11.1-18.4 months) compared to chemotherapy alone. However, outcomes remain suboptimal, necessitating exploration of novel predictive biomarkers and resistance mechanisms.

    Emerging evidence implicates chronic stress in cancer progression and treatment response. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, elevating cortisol, catecholamines, and glucocorticoids. These hormones suppress immune function by reducing CD8+ T cells and natural killer (NK) cell activity while increasing immunosuppressive cells (e.g., regulatory T cells, myeloid-derived suppressor cells). Preclinical studies link chronic stress to metastasis via extracellular trap (NET) formation, impaired antitumor immunity, and resistance to PD-1/PD-L1 blockade. Clinically, chronic stress correlates with worse survival in non-small-cell lung cancer patients receiving ICIs. Despite these findings, psychological screening remains underutilized in oncology. This study aims to investigate the impact of chronic stress on ICI efficacy in advanced gastric cancer.

  2. Objectives

    Primary Objective:

    Evaluate the association between chronic stress and tumor response (via Tumor Regression Grade, TRG) in advanced gastric cancer patients undergoing neoadjuvant immunotherapy.

    Secondary Objectives:

    Assess the effect of chronic stress on post-gastrectomy quality of life (QoL).

    Analyze correlations between chronic stress biomarkers and survival outcomes (PFS, OS).

  3. Study Endpoints

    Primary Endpoint:

    Pathological response assessed by TRG (Mandard criteria).

    Secondary Endpoints:

    QoL (EORTC QLQ-C30/STO22 questionnaires).

    PFS and OS.

    Exploratory Endpoints:

    Dynamic changes in chronic stress biomarkers (serum cortisol, ACTH, epinephrine, norepinephrine, serotonin).

    Correlation of biomarker levels with TRG and survival.

  4. Study Design Type: Single-center, prospective observational study. Duration: 36 months. Sample Size: 268 patients (134 high chronic stress, 134 low chronic stress).

    Inclusion Criteria:

    Age 18-75 years.

    Histologically confirmed gastric adenocarcinoma (per Japanese Gastric Cancer Guidelines, 2017).

    Scheduled for neoadjuvant immunotherapy + radical gastrectomy.

    Informed consent.

    Exclusion Criteria:

    Pregnancy/breastfeeding.

    Prior upper abdominal surgery (excluding cholecystectomy).

    Active infection, autoimmune disease, or corticosteroid use within 1 month.

    Psychiatric disorders or investigator-deemed unsuitability.

    Withdrawal Criteria:

    Patient request, loss to follow-up, or safety concerns.

  5. Methods

    Chronic Stress Assessment:

    Validated psychological questionnaires (e.g., Hospital Anxiety and Depression Scale) at baseline and treatment milestones.

    Biomarker analysis: Serum cortisol, ACTH, epinephrine, norepinephrine, serotonin at key timepoints (pre-treatment, post-neoadjuvant therapy, post-surgery).

    Clinical Data Collection:

    TRG evaluation post-surgery.

    QoL assessments at 1, 3, 6, 12, 18, 24, and 36 months post-surgery.

    Survival tracking via hospital records and follow-up visits.

    Statistical Analysis:

    Stratification by baseline stress scores (high/low).

    Cox regression for survival outcomes; logistic regression for TRG-QoL correlations.

    Significance threshold: *p* \< 0.05.

  6. Significance This study addresses a critical gap in understanding how psychological factors modulate ICI efficacy. By identifying chronic stress as a predictor of treatment response, results may guide personalized interventions (e.g., beta-blockers, behavioral therapy) to improve outcomes in advanced gastric cancer.
Read the detailed description

Gastric carcinoma (GC) remains a globally important cancer, with more than one million new cases and an estimated 769,000 deaths in 2020(equivalent to one in every 13 deaths worldwide) , it ranks fifth globally in incidence and fourth globally in mortality [1] . In China, 80% of gastric cancer patients are advanced, and the standard recommendation for locally advanced gastric cancer is perioperative adjuvant chemotherapy plus standard gastrectomy plus radical lymphadenectomy [2,3] . A series of large phase III studies (including Checkmate-649, ATTRACTION-04, KEYNOTE-062, ORIENT-16[4,5,6,7]) of completed ICI plus chemotherapy in gastric/esophageal/GEJ cancer showed a median PFS of 2.8 to 10.5 months for patients treated with ICI plus chemotherapy, median OS was 11.1-18.4 months. For advanced gastric/oesophagogastric junction gastric/oesophagogastric cancer, immunotherapy combined with chemotherapy versus first-line chemotherapy resulted in clinically meaningful PFS benefit, improved and durable objective responses, maintenance of HRQOL, and improved survival, also acceptable safety profile [4,5,6,7] , but the prognosis of advanced gastric cancer remains poor. There is still a lot of room for exploration to improve the efficacy of adjuvant therapy. It is imperative to find new predictive markers of immunotherapy efficacy, and explore the mechanism of drug resistance to immune checkpoint inhibitors.

In addition to genetic and tumor microenvironmental factors, psychological factors may also play a role in cancer treatment [8] . Chronic stress refers to the persistent non-specific adaptive response of the body triggered by the activation of the hypothalamic-pituitary-adrenal, glandular axis and sympathetic nervous system under the stimulation of physiological and psychological stressors, anxiety and depression. Chronic stress can affect the functioning of the immune system [9,12,13] . Related studies have shown that there may be different mechanisms by which chronic stress affects the progression and treatment of gastric cancer: depression induces neuroendocrine phenotypes through the catecholamine/β2-AR/MACC1 axis, thereby accelerating the invasion and metastasis of gastric cancer [6] ; Chronic stress, which activates the hypothalamic-pituitary-adrenal axis as well as the sympathetic nervous system, causes increased levels of cortisol, adrenergic hormones, the glucocorticoid released during chronic stress leads to the formation of NETs (extracellular traps) and the establishment of a microenvironment that promotes metastasis, which may contribute to the development of metastatic lesions, whereas digestion of NETs with DNase I in experimental mice prevents chronic stress-induced metastasis [11] . The stress-glucocorticoid-tsc22D3 axis can impair therapy-induced, antitumor immunity [12] . Preclinical studies have shown that pain-induced activation of the HPA axis and subsequent glucocorticoid, release can elicit anti-inflammatory effects, including apoptosis of T lymphocytes and neutrophil [13] . Endogenous glucocorticoids, the persistent release of hormones, also inhibit antigen presentation, further undermining systemic immune function [13] . In a large number of animals, studies have shown that exposure to chronic stress causes depression-like and anxiety-like symptoms in mice, thereby promoting tumor progression and metastasis [14,15,16] . Stress hormones can directly affect the malignant molecular characteristics of tumor cells [14,17,18] . Preclinical studies have shown that chronic stress also plays a potential role in promoting the development of the immunosuppressive tumor microenvironment [14,19,20] . Chronic stress exposure reduces CD8 + T cells and natural killer cells Proportion of cells and inhibit their function, while also increasing the infiltration of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells [12,19,21] . In mouse tumor models, studies have shown that chronic stress impairs the response to programmed cell death-1(PD-1)/PD-L1 blockade [12,22] . Chronic stress is also strongly associated with cancer, patient outcomes, and survival outcomes, as those with symptoms of depression or anxiety are at increased risk of relapse and Mortality[23]. However, screening and monitoring of psychological status in the clinic is often neglected and is not part of the current diagnosis and treatment routine [14] .

As immunotherapy becomes the cornerstone of treatment, it is crucial and important to study the relationship between chronic stress and the efficacy of ICIs. Studies have shown an association between chronic stress and worse clinical prognosis in patients with advanced non-small-cell lung carcinoma treated with ICIS, which highlights the potential significance of chronic stress in cancer management [24] . A 2020 study found that in colorectal cancer, β receptor and COX2 inhibition by preoperative propranolol/Idolac improved tumor metastasis, immunity, and inflammatory response-related markers [25] ; Similar results have been reported in breast cancer [26,27] . Psychological distress may have some predictive power for selected cancer presentations, including gastric cancer [28] . However, for gastric cancer, clinical evidence supporting the relationship between chronic stress and ICIS efficacy is limited, underscoring the need for prospective clinical studies.

03

Conditions studied

  • Gastric Cancers

Browse trials for

Keywords

  • Psychological Distress
  • Immune Checkpoint Inhibitors
  • Gastric Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population was patients with gastric cancer who were scheduled for laparoscopic gastrectomy after preoperative immunotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of ;
  • 18≦ age ≦75 years;
  • Sex: no limitation;
  • Patients with gastric adenocarcinoma diagnosed according to the 15th edition of the Japanese gastric cancer statute, 2017, after endoscopic of the primary lesion;
  • Patients requiring preoperative therapy at the discretion of the treating physician, followed by radical gastrectomy.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding;
  • Serious mental illness;
  • History of upper abdominal surgery (except for laparoscopic cholecystectomy) ;
  • Patients with gastric cancer who do not wish to undergo immunotherapy;
  • Patients with a history of continuous systemic therapy within the past 1 month;
  • Patients with active infection, active or disease, or uncontrolled systemic disease;
  • Patients at the discretion of the investigator, were deemed unsuitable for participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
268 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Gastric cancer patients who plan to reveive immune checkpoint inhibitors treatment

    As this was an observational study, no additional visits or laboratory analyses or assessments other than those required by routine, clinical practice were required. Patients must sign an updated informed consent form (ICF- approved by Ethics Committeettee) before performing data collection. After obtaining the patient's informed consent, the patient's clinical routine diagnosis and treatment information will be collected; We collected psychological assessment questionnaires, quality of life assessment questionnaires, serum cortisol, corticotropin (ACTH) , plasma epinephrine (Epi) , and noradrenaline (NE) 、serotonin along with clinical diagnosis and treatment nodes, data, the number and time of the study visits were according to the time points of the routine clinical patient review ( peritoneal exploration for advanced gastric cancer, 4 cycles of immunotherapy/combined chemotherapy before surgery, surgery, treatments after surgery) .

06

What researchers measure

Primary outcomes

  1. Tumor Regression Grade (TRG)

    Tumor Regression Grade (TRG) is a histopathological scoring system used to assess the degree of tumor response to neoadjuvant therapy (e.g., chemotherapy or radiation) in resected specimens. It quantifies residual viable tumor cells versus treatment-induced fibrosis or necrosis, providing prognostic and therapeutic guidance.

    Time frame: 7 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 23 months is below that.

Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 4, 2025
StartActual
Jan 3, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07003334
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Jan 3, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 4, 2025

Study contacts

Xinhua Chen, Ph.D
Contact
xinhuachen03@163.com
8615626452302

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion